Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188%
Key takeaways
- VKTX INTC TFC NVDA An analyst at the banking giant Truist Financial has an $83 price target on Viking Therapeutics (NASDAQ: VKTX), which is particularly notable given that Viking opened at $28.75 per share on June 8.
- The clinical-stage company lacks commercial products, but it has a promising weight-loss drug candidate, VK2735, in phase 3 trials.
- Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need.
VKTX INTC TFC NVDA An analyst at the banking giant Truist Financial has an $83 price target on Viking Therapeutics (NASDAQ: VKTX), which is particularly notable given that Viking opened at $28.75 per share on June 8. If it reached that target from that June 8 opening price, that would be a gain of 188%.
The clinical-stage company lacks commercial products, but it has a promising weight-loss drug candidate, VK2735, in phase 3 trials. The rewards for getting the drug to market could be substantial, which the bold price target reflects. But so too are the risks for investors.
Will AI create the world s first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »